

EUROPEAN
CURRICULUM VITAE



PERSONAL INFORMATION

Surname **GENOVESE**
Name **STEFANO**
Nationality Italian

Date of birth

Private Address

Telephone

E-mail

Institutional Address
CENTRO CARDIOLOGICO MONZINO IRCCS
DIABETES, ENDOCRINE AND METABOLIC DISEASES UNIT

Mobile

Office Telephone

Fax

E-mail

Tax Code

VAT Code

Member of The Milan College of
Physicians and Dentists

WORK EXPERIENCE

• 8/9/2017 – To date

- Name and address of employer
- Type of business or sector
- Main activities and responsibilities

Centro Cardiologico Monzino IRCCS, Via Carlo Parea, 4 – 20138 Milano (MI)
Head of Diabetes, Endocrine and Metabolic Diseases Unit
Head of Clinical and Research Activities in Diabetes, Endocrine and Metabolic Diseases

1/5/2010 – 8/9/2017

- Name and address of employer
- Type of business or sector
- Main activities and responsibilities

Multimedica IRCCS, Via Milanese, 300 – 20099 Sesto San Giovanni (MI)
Head of Diabetes and Metabolic Diseases Unit
Head of Diabetes and Metabolic Diseases Area Cardiovascular and Metabolic Department –
IRCCS Multimedica

• 1/7/2013 – 8/9/2017

- Name and address of employer
- Type of business or sector
- Main activities and responsibilities

Multimedica Castellanza, Via Piemonte, 70 – 21053 Castellanza (VA)
Head of Diabetes and Endocrine Outpatient Clinic
Head of Diabetes and Metabolic Diseases Area Cardiovascular and Metabolic Department –
IRCCS MultiMedica

• 1/7/2011 – 1/7/2013

- Name and address of employer
- Type of business or sector

Multimedica Castellanza, Via Piemonte, 70 – 21053 Castellanza (VA)
Head of Internal Medicine and Diabetes Unit

TEACHING ACTIVITIES

- **From Academic year 2011-2012**

To date

- Type of Teaching

Teaching contract in the Postgraduate School of Endocrinology and Metabolic Diseases at San Raffaele Vita-Salute University – Milan.

- **From Academic year 2012-2013 to 2013-2014**

- Type of Teaching

Professor of Pathology in the Course Degree in Nursing, University of Milan, at the San Giuseppe Hospital – Gruppo Multimedita (15 hours/year).

- **From Academic year 2006-2007 to 2009-2010**

- Type of Teaching

Professor of Endocrinology in the Course Degree in Nursing, University of Milan, at the Istituto Clinico Humanitas (15 hours/year).

- **From Academic year 2006-2007 to 2009-2010**

- Type of Teaching

Teaching contract in the Integrated Course of Semiotics and Systematics II, School of Medicine and Surgery of the University of Milan, at the Istituto Clinico Humanitas (Scientific Sector MED/13 Endocrinology).

- **Academic year 2005-2006**

- Type of Teaching

Teaching contract in the Integrated Course of Semiotics and Systematics II, School of Medicine and Surgery of the University of Milan, at the Istituto Clinico Humanitas (Scientific Sector MED/09 Internal Medicine).

EDUCATION AND TRAINING

- **From academic year 1998-1999 to 2002-2003**

- Name and type of organisation providing education and training
- Title of qualification awarded
- Thesis Title

Postgraduate School in Endocrinology and Metabolic Diseases, University of Milan

Specialist in Endocrinology and Metabolic Diseases

"Adulthood onset of Type 1 Diabetes Mellitus (immune-mediated). Prevalence and clinical characteristics of a large sample of Italian patients" – 3rd March 2004

- **From academic year 1985-1986 to 1989-1990**

- Name and type of organisation providing education and training
- Title of qualification awarded
- Thesis Title

Postgraduate School in Internal Medicine, University of Milan

Specialist in Internal Medicine

"Immunoserological markers of type 1 diabetes: cross-sectional analysis of a family study" – 16th July 1990

- **November 1985**

- Name and type of organisation providing education and training
- Title of qualification awarded

University of Milan

MD Qualifying Examination

- **From academic year 1979-1980 to 1984-1985**

- Name and type of organisation providing education and training
- Title of qualification awarded
- Thesis Title

Medical School, University of Milan

Medical Doctor (Cum Laude)

"Plasma and erythrocyte folic acid in alcoholic hepatitis" – 17th July 1985

• July 1979

- Name and type of organisation providing education and training
- Title of qualification awarded

Liceo Ginnasio "G. Bercet", Milan

Maturità Classica

PERSONAL SKILLS AND COMPETENCES

CLINICAL ACTIVITY
(ANNEX 1 – CLINICAL RESEARCH)

Outpatient and Inpatient Clinic in: Diabetes, Endocrinology, Metabolic Diseases, Nutrition and Internal Medicine.

Principal Investigator in clinical trials according to GCP (n° 55 from 1998 to date - phase IIa, IIIa e IIIb, IV and observational). In 5 studies had also the role of National Coordinator (four phase III studies and one observational study).

RESEARCH TOPICS

Autoimmunity of the endocrine system:

- etiopathogenesis of type 1 diabetes and other autoimmune endocrinopathies;
- identification and characterization of antigens in the autoimmune processes;
- methods of autoantibody determinations.

Population studies and identification of markers for prediction of type 1 diabetes and for prediction and early diagnosis of type 2 diabetes.

Therapy of type 2 diabetes mellitus (Effects of drugs and glycaemic variability.)

Cardiovascular complications of diabetes mellitus.

GRANTS AND FUNDING

DIARIO Project (Italian Ministry of Economic Development 2016).

LECTURES, SEMINARS AND CHAIRMANSIPS

Speaker and Chairman at numerous national and international congresses, conferences, conventions and seminars.

EDITOR AND REFEREE OF SCIENTIFIC JOURNALS

From 2014 to 2015 Associate Editor of Acta Diabetologica

Member of the Advisory Board of Acta Diabetologica

Referee for:

Acta Diabetologica, Cardiovascular Diabetology, Diabetes Technology and Therapeutics, Diabetes and Metabolism Research and Reviews, Diabetes & Vascular Disease Research, Diabetic Medicine, Diabetologia, Endocrine, European Journal of Endocrinology, International Journal of Cardiology, Journal of Autoimmunity, Journal of Endocrinological Investigation, PlosOne

SCIENTIFIC SOCIETES

SOCIETÀ ITALIANA DI DIABETOLOGIA (SID)

- ORDINARY MEMBER
- 2001 - 2004 MEMBER OF THE COMMITTEE OF THE STUDY GROUP ON "TYPE 1 DIABETES"
- FROM 2002 TO 2006 MEMBER OF THE SCIENTIFIC BOARD
- FROM 2005 TO 2014 MEMBER OF THE SCIENTIFIC COMMITTEE OF NIRAD

ASSOCIAZIONE MEDICI DIABETOLOGI (AMD)

- ORDINARY MEMBER
- FROM 2010 TO 2017 REGIONAL TUTOR FOR AMD ANNALS
- FROM 2011 TO 2013 MEMBER OF CENTRO STUDI E RICERCHE (CSR)
- FROM 2013 TO 2015 MEMBER OF THE FONDAMD ONLUS BOARD

EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD)

- ORDINARY MEMBER
- FROM 2014 TO 2018 SECRETARY OF DIABETES & CARDIOVASCULAR DISEASES STUDY GROUP

SOCIETÀ ITALIANA DI NEFROCARDIOLOGIA (SINCAR)

- ORDINARY MEMBER
- FROM 2020 MEMBER OF THE BOARD

SOCIETÀ ITALIANA DI TELEMEDICINA (SIT)

- ORDINARY MEMBER

PRIZES

Premio della Società Italiana di Diabetologia - Sezione Regionale Lombarda (Bergamo, 11 novembre 1995)

Premio 'Boehringer Mannheim-Italia', 14° Congresso della Società Italiana di Diabetologia (Genova, 17-20 maggio 1992).

Premio di Studio della 'Fondazione Emilio Trabucchi', Dipartimento di Farmacologia, Università degli Studi di Milano (1986).

PUBLICATIONS
(ANNEX 2)

Author or co-author in:

- 130 original papers on peer reviewed journals: 95 originals as principal author or co-author, 20 originals as collaborator and 15 reviews.
- *Google Scholar on May 7th, 2021*
Total Citations = 10742, H index = 43, i10-index = 86
Citations from 2016 = 6185, H index = 37, i10-index = 70
- *Scopus on May 7th, 2021*
h-index 34

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

	ENGLISH
• Reading skills	Excellent
• Writing skills	Excellent
• Verbal skills	Excellent

	FRENCH
• Reading skills	Excellent
• Writing skills	Good
• Verbal skills	Excellent

ANNEXES

- 1 - Clinical Trials
- 2 - Original Papers on Peer Reviewed Journals

Milan, 7/05/2021


Dott. Stefano Genovese

I authorize the processing of my personal data in accordance with the Decreto Legislativo 30 giugno 2003, n. 196: "Codice in materia di protezione dei dati personali".

ANNEX 1: CLINICAL TRIALS

1. BRL 49653/136 "Studio randomizzato della durata di 26 settimane multicentrico, in doppio cieco, controllato verso placebo, volto a valutare l'efficacia, sicurezza e tollerabilità di rosiglitazone in associazione a terapia con insulina e/o sulfonilurea in pazienti affetti da diabete mellito di tipo 2 con insufficienza renale cronica (non in dialisi)".
2. AD 4833/98/I-02 "Efficacy and safety of Pioglitazone in patients with type 2 diabetes mellitus in comparison with Gliclazide".
3. BRL 49 653/048 "Studio comparativo randomizzato, in doppio cieco, teso a valutare l'effetto della monoterapia con Rosiglitazone Metformina Glibenclamide sul controllo glicemico e sulla funzione b-cellulare in pazienti affetti da diabete mellito di tipo 2, di diagnosi recente (≤ 2 anni), non trattati in precedenza con farmaci ipoglicemizzanti".
4. ANA-1198 "A four-month multicentre, randomized parallel, open-label, efficacy and safety comparison of insulin aspart and human soluble insulin as meal related insulin in a basal-bolus injection regimen in suboptimally controlled subjects with type 2 diabetes".
5. NN304-1336 "A six-month, multi-center, open, asymmetrically randomized, parallel, efficacy and safety comparison of insulin Detemir and NPH insulin in subjects with type 2 diabetes on a basal-bolus regimen".
6. HOE 901/4019 (LANTUS) "Transfer of patients with type 1 diabetes mellitus from NPH to glargine as basal insulin: a multicenter, randomised, parallel group, open label study".
7. CDJN608B2302 - NAVIGATOR "Uno studio internazionale, randomizzato, in doppio cieco con placebo, fattoriale 2x2 sull'efficacia e la sicurezza della somministrazione a lungo termine di niteglinide e valsartan nella prevenzione del diabete e delle complicanze cardiovascolari nei soggetti con intolleranza al glucosio".
8. DEMAND "A multicenter, randomized, prospective, double-blind study to evaluate the nephroprotective effect of Delapril alone or combined with Manidipine in patients with type 2 diabetes".
9. BAY 38-9456/1078.
10. PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin.
11. PIOC/RCV10/TIF "Effetti del Pioglitazone sui marcatori di rischio cardiovascolare in pazienti con diabete mellito di tipo 2".
12. DYDA "Left ventricular dysfunction in diabetes".
13. 901 Develogen/Andromeda - Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients (DIA-AID).
14. PROMISE DIA "Prevalenza della adiposità intra-addominale e della sindrome metabolica nel diabete mellito di tipo 2".
15. PIOC/LAN07/TIF "Pioglitazone Randomized Italian Study on Metabolic syndrome (PRISMA). Double-blind, randomized, multicenter, parallel-group study to evaluate the effects of pioglitazone on metabolic syndrome in patients with type 2 diabetes treated with metformin". **(Coordinatore Nazionale: Dr. Stefano Genovese)**
16. D1680C00002 "Studio di 18 settimane, internazionale, multicentrico, randomizzato, a gruppi paralleli, in doppio cieco, controllato verso farmaco attivo, di fase IIIb, per valutare l'efficacia e la sicurezza di Saxagliptina in associazione con Metformina, in confronto a Sitagliptina in associazione con Metformina, in pazienti adulti con diabete mellito di tipo 2, che hanno un controllo inadeguato delle glicemie in terapia con sola metformina. (SAXA) - 02".
17. UPGRADE "A multicentre, open label, nonrandomised, non-interventional, observational, safety study in subjects using Insulin Aspart (NovoRapid®) or Soluble Human Insulin for the treatment of diabetes mellitus".
18. LAUREL "Effetti metabolici del cambiamento della terapia insulinica in pazienti con diabete mellito di tipo 2 - Utilizzo a lungo termine nella vita reale".
19. MK0431 "Studio clinico di Fase III, multicentrico, randomizzato, in doppio cieco per valutare la sicurezza e l'efficacia dell'aggiunta di sitagliptin rispetto all'aggiunta di glimepiride in pazienti affetti da diabete mellito Tipo 2 scarsamente compensati con metformina".

20. GETGOAL-F1 "EFC10743 "Studio multicentrico in doppio cieco, randomizzato, a gruppi paralleli, controllato vs placebo, della durata di 24 settimane seguite da un periodo di estensione, per valutare l'efficacia e la sicurezza di AVE0010, in due regimi di titolazione, in aggiunta a metformina in pazienti con diabete di tipo 2 non adeguatamente controllati dalla metformina".
21. SUNRISE - "Studio osservazionale su pazienti con diabete di tipo 2 trattati con Eucreas® (vildagliptina/metformina) per valutare gli esiti della terapia così come riportati dai pazienti (soddisfazione del paziente, produttività, utilizzo delle risorse)". **(Coordinatore Nazionale: Dr. Stefano Genovese)**
22. H8O-IT-B014 Exenatide and Basal Insulins Use in the Real Setting: an Italian Observational Study in Patients with Type 2 Diabetes and Secondary Failure of Oral Antihyperglycemic Treatment (EBIRIOS).
23. MOLT-2009-01 (EudraCT Nr 2010-019598-13) A randomised, double-blind, dose-response, placebo-controlled, multicenter, phase IIA clinical study to evaluate the efficacy and safety of topical application of G.68.γ/EtOH in patients with type 1 or type 2 diabetes with infected foot ulcers. Diabetic ulcer Antimicrobial New Topical treatment Evaluation (DANTE).
24. BI 1218.74 (EudraCT Nr 2009-013157-15) A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high cardiovascular risk. The CAROLINA Trial.
25. SYR-322_402 (EudraCT Nr 2009-011222-34) A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome (EXAMINE).
26. PREVAIL STUDY Pan European prevalence assessment of diabetic macular edema with visual impairment.
27. BCB 109 EXCSEL (EudraCT Nr 2010-021069-63) A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with exenatide once weekly in Patients with Type 2 Diabetes Mellitus.
28. Protocol I2R-MC-BIAJ(a) (EudraCT Nr 2011-000842-39) A Comparison of LY2605541 versus Insulin Glargine as Basal Insulin Treatment in Combination with Oral Anti-Hyperglycemia Medications in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: A Double-Blind, Randomized Study. The IMAGINE 2 Study.
29. TOSCA.IT (EudraCT Nr 2008-000738-39) Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents Intervention Trial (Studio di fase IV).
30. BI 1275.10 (EudraCT Nr 2012-002271-34) A phase III, randomized, double-blind, parallel group study to evaluate the efficacy and safety of linagliptin 5 mg compared to placebo, administered as oral fixed dose combination with empagliflozin 10 mg or 25 mg for 24 weeks, in patients with type 2 diabetes mellitus and insufficient glycaemic control after 16 weeks of treatment with empagliflozin 10 mg or 25 mg on metformin background therapy. **(Coordinatore Nazionale: Dr. Stefano Genovese)**
31. MK3102-018-01 (EudraCT Nr 2012-002414-39) A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus.
32. MK 0431D_266-00 (EudraCT Nr 2012-001868-29) A Phase III, Randomized, Double-Blind, Clinical Trial to Study the Efficacy and Safety of MK-0431D (a fixed-dose combination [FDC] of sitagliptin and simvastatin) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) with Inadequate Glycemic Control on Metformin Monotherapy. **(Coordinatore Nazionale: Dr. Stefano Genovese)**
33. CLAF237AIT03 Studio osservazionale, multicentrico, prospettico, della durata di 3 anni, per valutare, attraverso questionari dedicati, gli esiti riportati dai pazienti in soggetti anziani (≥65 anni) affetti da diabete mellito di tipo 2, trattati con duplice terapia orale a causa del fallimento di un regime di metformina in monoterapia. The 3 AGE study.
34. TAK-875_302 (EudraCT 2011-001752-10) A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg compared to Placebo and Sitagliptin 100 mg When Used in Combination with Metformin in Subjects with Type 2 Diabetes.
35. TAK-875_306 (EudraCT 2011-001732-37) A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects with Type 2 Diabetes and with Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events.

36. EX1250-4080 (EudraCT 2013-002371-17) A trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events. DEVOTE Trial.
37. NN9211-4083 ADJUNCT TWO (EudraCT no.: 2012-005778-74) The efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetes. A 26-weeks randomised, insulin capped, placebo-controlled, double-blind, parallel group, multinational, multi-centre trial.
38. CANVAS – R (EudraCT No. 2013-003050-25) A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus.
39. Protocol 28431 754DNE3001 (EUDRACT number: 2013-004494-28) A Randomized, Double-blind, Event-driven, Placebo controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy. The “CREDESCENCE” Trial (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial).
40. Protocol n. EFC13403 (EudraCT Number: 2014-002844-42) Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog® in Adult Patients With Type 2 Diabetes Mellitus also Using Insulin Glargine. Sorella-2 Trial.
41. Clinical Protocol MB102229 (EudraCT Number: 2013-004674-97) A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus.
42. DYDA 2 TRIAL Protocol Number G113 (EudraCT No. 2014-004683-38) Effects of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin on left ventricular myocardial DYsfunction in patients with type 2 DiAbetes mellitus and concentric left ventricular geometry.
43. DISCOVER Study D1690R00002: DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings.
44. Study GLP111892 (EudraCT Number: 2014-001969-27) Albiglutide Versus Placebo as Add-on to Intensified Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus.
45. Study ID: NN2211-4118 Real Study Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice Non-interventional retrospective multicenter study.
46. Study GLARGL07537 (Codice EudraCT n: 2015-001167-39) National, Randomized, Controlled, Open-label, Parallel-Group Study comparing the efficacy and safety of two different titration algorithm approaches (physician managed vs patient managed) for new insulin glargine U300 therapy in type 2 diabetes patients.
47. Protocol BI 1245.72 (EUDRACT number: 2014-005256-26) A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to insulin thErapy over 26 weeks in patients with Type 1 Diabetes
48. Protocol LPS14060 - (EUDRACT number: 2015-001832-39) A twenty-six week, randomized, open-label, 2-arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of transition to Toujeo® compared to standard of care insulin, in basal insulin treated patients with uncontrolled type 2 diabetes mellitus, with six-month extension (Regain Control)
49. Protocol LPS14584 - (EUDRACT number: 2015-005101-36) A 24-week, multicenter, randomized, open-label, parallel-group study comparing the efficacy and safety of Toujeo® and Tresiba® in insulin-naïve patients with type 2 Diabetes Mellitus not adequately controlled with Oral Antidiabetic Drug(s) ± GLP-1 receptor agonist (BRIGHT)
50. Boehringer Ingelheim/1245.110 Title: A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF). EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure. EMPEROR-Preserved
51. Boehringer Ingelheim/1245.121 Title: A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF). EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure. EMPEROR-Reduced
52. Protocol I8F-MC-GPGH: A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 versus Titrated Insulin Degludec on Glycemic Control in Patients with Type 2 Diabetes (SURPASS-3)

53. Protocol EX9924-4473 (EudraCT Number 2018-003141-42): Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes (SOUL)
54. Protocol MOLT-2019-01: A Randomized, Open-Label, Multicentre Clinical Study To Evaluate The Efficacy And Safety Of Topical Applications Of the System VULNOFAST® plus / VULNOLIGHT® In Addition To The Usual Care Versus Usual Care Alone For The Treatment Of Infected Foot Ulcers In Diabetic Patients – PHOTOFINISH Study.
55. Protocol I8F-MC-GPGN The Effect of Tirzepatide versus Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)

ANNEX 2: ORIGINAL PAPERS ON PEER REVIEWED JOURNALS

1. Cosentino N, Bonomi A, Campodonico J, Veglia F, De Ferrari GM, **Genovese S**, Marenzi G. May the In-Hospital Mortality Gap between STEMI Patients with and without Diabetes Mellitus Be Reduced? The Cardio-Renal Hypothesis. *Nutr Metab Cardiovasc Dis.* 2021; doi: <https://doi.org/10.1016/j.numecd.2021.02.003>
2. Orsini Federici M, Gentilella R, Corcos A, Torre E, **Genovese S**. Changing the approach to type 2 diabetes treatment: A comparison of glucagon-like peptide-1 receptor agonists and sulphonylureas across the continuum of care. *Diabetes Metab Res Rev.* 2021; Early View doi.org/10.1002/dmrr.3434
3. Baviera M, **Genovese S**, Lepore V, Colacioppo P, Robusto F, Tettamanti M, D'Ettorre A, Avanzini F, Fortino I, Nicolucci A, Roncaglioni MC, Giorgino F. Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts. *Diabetes Obes Metab.* 2021 Feb 19; doi: 10.1111/dom.14361. [Epub ahead of print] PubMed PMID: 33606897.
4. Milazzo V, Cosentino N, **Genovese S**, Campodonico J, Mazza M, De Metrio M, Marenzi G. Diabetes Mellitus and Acute Myocardial Infarction: Impact on Short and Long-Term Mortality. *Adv Exp Med Biol.* 2021;1307:153-169. doi: 10.1007/5584_2020_481. Review. PubMed PMID: 32020518.
5. Trevisan R, Grosu A, Avogaro A, Agostoni P, Ceconi C, **Genovese S**, Bossi A, Piti A, Senni M, Maggioni AP. [Grey zones on diabetes in cardiovascular disease. Expert opinion]. *G Ital Cardiol (Rome).* 2020 Dec;21(12):916-922. doi: 10.1714/3472.34545. PubMed PMID: 33231210.
6. Lucci C, Cosentino N, **Genovese S**, Campodonico J, Milazzo V, De Metrio M, Rondinelli M, Riggio D, Biondi ML, Rubino M, Celentano K, Bonomi A, Capra N, Veglia F, Agostoni P, Bartorelli AL, Marenzi G. Prognostic impact of admission high-sensitivity C-reactive protein in acute myocardial infarction patients with and without diabetes mellitus. *Cardiovasc Diabetol.* 2020 Oct 20;19(1):183. doi: 10.1186/s12933-020-01157-7. PubMed PMID: 33081810; PubMed Central PMCID: PMC7576820.
7. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F (on behalf of Emperor Reduced Trial investigators including **Genovese S**). Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *N Engl J Med.* 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28. PubMed PMID: 32865377.
8. Vinci MC, Gambini E, Bassetti B, **Genovese S**, Pompilio G. When Good Guys Turn Bad: Bone Marrow's and Hematopoietic Stem Cells' Role in the Pathobiology of Diabetic Complications. *Int J Mol Sci.* 2020 May 29;21(11). doi: 10.3390/ijms21113864. Review. PubMed PMID: 32485847; PubMed Central PMCID: PMC7312629.
9. Sangalli E, Tagliabue E, Sala L, Prattichizzo F, Uccellatore A, Spada D, Lorino F, de Candia P, Lupini S, Cantone L, Favero C, Madeddu P, Bollati V, **Genovese S**, Spinetti G. Circulating MicroRNA-15a Associates With Retinal Damage in Patients With Early Stage Type 2 Diabetes. *Front Endocrinol (Lausanne).* 2020;11:254. doi: 10.3389/fendo.2020.00254. eCollection 2020. PubMed PMID: 32390950; PubMed Central PMCID: PMC7192007.
10. Lapolla A, **Genovese S**, Giorgino F, Disoteo O, Sartore G, Bartzaghi M, Del Prato S. Patient-reported outcomes in elderly patients with type 2 diabetes mellitus treated with dual oral therapy: a multicenter, observational study from Italy. *Curr Med Res Opin.* 2020 Apr;36(4):555-562. doi: 10.1080/03007995.2019.1707649. Epub 2020 Jan 9. PubMed PMID: 31868033.
11. Cosentino N, **Genovese S**, Campodonico J, Bonomi A, Lucci C, Milazzo V, Moltrasio M, Biondi ML, Riggio D, Veglia F, Ceriani R, Celentano K, De Metrio M, Rubino M, Bartorelli AL, Marenzi G. High-Sensitivity C-Reactive Protein and Acute Kidney Injury in Patients with Acute Myocardial Infarction: A Prospective Observational Study. *J Clin Med.* 2019 Dec 12;8(12). doi: 10.3390/jcm8122192. PubMed PMID: 31842300; PubMed Central PMCID: PMC6947188.
12. Giorda CB, Cioffi G, Lucci D, Nada E, Ognibeni F, Mancusi C, Latini R, Maggioni AP (on behalf of DYDA 2 Trial Investigators including **Genovese S**). Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population. *Cardiovasc Drugs Ther.* 2019 Oct;33(5):547-555. doi: 10.1007/s10557-019-06898-6. PubMed PMID: 31418140.

13. Marenzi G, Cosentino N, **Genovese S**, Campodonico J, De Metrio M, Rondinelli M, Cornara S, Somaschini A, Camporotondo R, Demarchi A, Milazzo V, Moltrasio M, Rubino M, Marana I, Grazi M, Lauri G, Bonomi A, Veglia F, De Ferrari GM, Bartorelli AL. Reduced Cardiorenal Function Accounts for Most of the In-Hospital Morbidity and Mortality Risk Among Patients With Type 2 Diabetes Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. *Diabetes Care*. 2019 May 2. pii: dc190047. doi: 10.2337/dc19-0047. [Epub ahead of print] PMID: 31048409
14. Avogaro A, Bonora E, Consoli A, Del Prato S, **Genovese S**, Giorgino F. Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome. *Diab Vasc Dis Res*. 2019 May 2:1479164119845612. doi: 10.1177/1479164119845612. [Epub ahead of print] PMID: 31044622
15. Vigorelli V, Resta J, Bianchessi V, Lauri A, Bassetti B, Agrifoglio M, Pesce M, Polvani G, Bonalumi G, Cavallotti L, Alamanni F, **Genovese S**, Pompilio G, Vinci MC. Abnormal DNA Methylation Induced by Hyperglycemia Reduces CXCR 4 Gene Expression in CD 34+ Stem Cells. *J Am Heart Assoc*. 2019 May 7;8(9):e010012. doi: 10.1161/JAHA.118.010012. PubMed PMID: 31018749.
16. Mirijello A, Viazzi F, Fioretto P, Giorda C, Ceriello A, Russo GT, Guida P, Pontremoli R, De Cosmo S; AMD ANNALS Study Group (including **Genovese S**). Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes. *BMC Nephrol*. 2018 Dec 4;19(1):347. doi: 10.1186/s12882-018-1136-6. PubMed PMID: 30514308; PubMed Central PMCID: PMC6280443.
17. Simioni N, Berra C, Boemi M, Bossi AC, Candido R, Di Cianni G, Frontoni S, **Genovese S**, Ponzani P, Provenzano V, Russo GT, Sciangula L, Lapolla A, Bette C, Rossi MC; ReaL (NN2211-4118) Study Group*. Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting. *Acta Diabetol*. 2018 Jun;55(6):557-568. doi: 10.1007/s00592-018-1124-0. Epub 2018 Mar 12. PubMed PMID: 29527621; PubMed Central PMCID: PMC5959971.
18. Marzona I, Avanzini F, Tettamanti M, Vannini T, Fortino I, Bortolotti A, Merlino L, **Genovese S**, Roncaglioni MC. Prevalence and management of diabetes in immigrants resident in the Lombardy Region: the importance of ethnicity and duration of stay. *Acta Diabetol*. 2018 Apr;55(4):355-362. doi: 10.1007/s00592-018-1102-6. Epub 2018 Jan 22. PubMed PMID: 29357034.
19. Schnell O, Standl E, Catrinou D, **Genovese S**, Lalic N, Lalic K, Skrha J, Valensi P, Ceriello A. Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. *Cardiovasc Diabetol*. 2018 Feb 19;17(1):30. doi: 10.1186/s12933-018-0667-2. PubMed PMID: 29458368; PubMed Central PMCID: PMC5819256.
20. Lapolla A, Berra C, Boemi M, Bossi AC, Candido R, Di Cianni G, Frontoni S, **Genovese S**, Ponzani P, Provenzano V, Russo GT, Sciangula L, Simioni N, Bette C, Nicolucci A; NN2211-4118 Study Group. Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study. *Adv Ther*. 2017 Dec 21. doi: 10.1007/s12325-017-0652-2. [Epub ahead of print] PubMed PMID: 29270781.
21. La Spada A, Ntai A, **Genovese S**, Rondinelli M, De Blasio P, Biunno I. Generation of human induced pluripotent stem cells from Wolfram Syndrome type 2 patients bearing the c.103+1G>A CISD2 mutation for disease modeling. *Stem Cells Dev*. 2017 Dec 14. doi: 10.1089/scd.2017.0158. [Epub ahead of print] PubMed PMID: 29239282.
22. Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators (including **Genovese S**). The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. *Am J Nephrol*. 2017 Dec 13;46(6):462-472. doi: 10.1159/000484633. [Epub ahead of print] PubMed PMID: 29253846.
23. Cattaneo M, La Sala L, Rondinelli M, Errichiello E, Zuffardi O, Puca AA, **Genovese S**, Ceriello A. A donor splice site mutation in CISD2 generates multiple truncated, non-functional isoforms in Wolfram syndrome type 2 patients. *BMC Med Genet*. 2017 Dec 13;18(1):147. doi: 10.1186/s12881-017-0508-2. PubMed PMID: 29237418; PubMed Central PMCID: PMC5729406.
24. Scavini M, Rossi MC, Scardapane M, Nicolucci A, Manicardi V, Russo G, Di Bartolo P, Giorda CB, Musacchio N, Ceriello A, **Genovese S**, Molinari C, Dozio N; AMD-Annals Study Group. Portrait of women with type 1 or type 2 diabetes of childbearing age attending diabetes clinics in Italy: the AMD-Annals initiative. *Acta Diabetol*. 2017 Dec 5. doi: 10.1007/s00592-017-1076-9. [Epub ahead of print] PubMed PMID: 29209815.

25. de Candia P, Spinetti G, Specchia C, Sangalli E, La Sala L, Uccellatore A, Lupini S, **Genovese S**, Matarese G, Ceriello A. A unique plasma microRNA profile defines type 2 diabetes progression. *PLoS One*. 2017 Dec 4;12(12):e0188980. doi: 10.1371/journal.pone.0188980. eCollection 2017. PubMed PMID: 29200427.
26. Lorenzoni V, Baccetti F, **Genovese S**, Torre E, Turchetti G. Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy. *Clinicoecon Outcomes Res*. 2017 Nov 20;9:699-710. doi: 10.2147/CEOR.S141477. eCollection 2017. PubMed PMID: 29200879; PubMed Central PMCID: PMC5700761.
27. Ceriello A, De Cosmo S, Rossi MC, Lucisano G, **Genovese S**, Pontremoli R, Fioretto P, Giorda C, Pacilli A, Viazzi F, Russo G, Nicolucci A; AMD-Annals Study Group.. Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. *Diabetes Obes Metab*. 2017 Nov;19(11):1570-1578. doi: 10.1111/dom.12976. Epub 2017 Jul 10. PubMed PMID: 28432733.
28. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group (including **Genovese S**). Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2017 Sep 28;377(13):1228-1239. doi: 10.1056/NEJMoa1612917. Epub 2017 Sep 14. PubMed PMID: 28910237.
29. Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschöpe D, Thorén F, Xu J, Langkilde AM; DEPICT-1 Investigators (including **Genovese S**). Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. *Lancet Diabetes Endocrinol*. 2017 Sep 13. pii: S2213-8587(17)30308-X. doi: 10.1016/S2213-8587(17)30308-X. [Epub ahead of print] PubMed PMID: 28919061.
30. Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivelles AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G; Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group (including **Genovese S**); under the mandate of the Italian Diabetes Society.. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. *Lancet Diabetes Endocrinol*. 2017 Sep 12. pii: S2213-8587(17)30317-0. doi: 10.1016/S2213-8587(17)30317-0. [Epub ahead of print] PubMed PMID: 28917544.
31. Ausili D, Bulgheroni M, Ballatore P, Specchia C, Ajdini A, Bezze S, Di Mauro S, **Genovese S**. Self-care, quality of life and clinical outcomes of type 2 diabetes patients: an observational cross-sectional study. *Acta Diabetol*. 2017 Aug 29. doi: 10.1007/s00592-017-1035-5. [Epub ahead of print] PubMed PMID: 28852863.
32. Vecchione C, Villa F, Carrizzo A, Spinelli CC, Damato A, Ambrosio M, Ferrario A, Madonna M, Uccellatore A, Lupini S, Maciag A, Ryskalin L, Milanese L, Frati G, Sciarretta S, Bellazzi R, **Genovese S**, Ceriello A, Auricchio A, Malovini A, Puca AA. A rare genetic variant of BPIFB4 predisposes to high blood pressure via impairment of nitric oxide signaling. *Sci Rep*. 2017 Aug 29;7(1):9706. doi: 10.1038/s41598-017-10341-x. PubMed PMID: 28852218; PubMed Central PMCID: PMC5574984.
33. Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group (including **Genovese S**). Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. *N Engl J Med*. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12. PubMed PMID: 28605603.
34. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondou N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group (including **Genovese S**). Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med*. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12. PubMed PMID: 28605608.
35. Lansink M, Hofman Z, **Genovese S**, Rouws CHFC, Ceriello A. Improved Glucose Profile in Patients With Type 2 Diabetes With a New, High-Protein, Diabetes-Specific Tube Feed During 4 Hours of Continuous Feeding. *JPEN J Parenter Enteral Nutr*. 2017 Aug;41(6):968-975. doi: 10.1177/0148607115625635. Epub 2016 Jan 29. PubMed PMID: 26826263.

36. **Genovese S**, Mannucci E, Ceriello A. A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes. *Adv Ther.* 2017 Jul 3. doi: 10.1007/s12325-017-0499-6. [Epub ahead of print] Review. PubMed PMID: 28674957; PubMed Central PMCID: PMC5565650.
37. Avogaro A, Giaccari A, Fioretto P, **Genovese S**, Purrello F, Giorgino F, Del Prato S. A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus. *Expert Rev Clin Pharmacol.* 2017 Jul;10(7):763-772. doi: 10.1080/17512433.2017.1322507. Epub 2017 May 2. Review. PubMed PMID: 28431476.
38. Piscitelli P, Viazzi F, Fioretto P, Giorda C, Ceriello A, **Genovese S**, Russo G, Guida P, Pontremoli R, De De Cosmo S. Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative. *Sci Rep.* 2017 Jun 12;7(1):3313. doi: 10.1038/s41598-017-03551-w. PubMed PMID: 28607417; PubMed Central PMCID: PMC5468280.
39. Pacilli A, Viazzi F, Fioretto P, Giorda C, Ceriello A, **Genovese S**, Russo G, Guida P, Pontremoli R, De Cosmo S; AMD-Annals Study Group.. Epidemiology of diabetic kidney disease in adult patients with type 1 diabetes in Italy: The AMD-Annals initiative. *Diabetes Metab Res Rev.* 2017 May;33(4). doi: 10.1002/dmrr.2873. Epub 2017 Jan 10. PubMed PMID: 27935651.
40. Schnell O, Standl E, Catrinou D, **Genovese S**, Lalic N, Skra J, Valensi P, Rahelic D, Ceriello A. Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group. *Cardiovasc Diabetol.* 2017 Mar 11;16(1):35. doi: 10.1186/s12933-017-0508-8. PubMed PMID: 28284218; PubMed Central PMCID: PMC5346258.
41. Viazzi F, Piscitelli P, Giorda C, Ceriello A, **Genovese S**, Russo GT, Fioretto P, Guida P, De Cosmo S, Pontremoli R; AMD-Annals Study Group.. Association of kidney disease measures with risk of renal function worsening in patients with hypertension and type 2 diabetes. *J Diabetes Complications.* 2017 Feb;31(2):419-426. doi: 10.1016/j.jdiacomp.2016.10.030. Epub 2016 Oct 29. PubMed PMID: 27884661.
42. Testa R, Ceriotti F, Guerra E, Bonfigli AR, Boemi M, Cucchi M, Di Gaetano N, Santini G, **Genovese S**, Ceriello A. Glycated albumin: correlation to HbA1c and preliminary reference interval evaluation. *Clin Chem Lab Med.* 2017 Feb 1;55(2):e31-e33. doi: 10.1515/cclm-2016-0512. PubMed PMID: 27458664.
43. Viazzi F, Piscitelli P, Giorda C, Ceriello A, **Genovese S**, Russo G, Guida P, Fioretto P, De Cosmo S, Pontremoli R; AMD-Annals Study Group.. Metabolic syndrome, serum uric acid and renal risk in patients with T2D. *PLoS One.* 2017 Apr 19;12(4):e0176058. doi: 10.1371/journal.pone.0176058. eCollection 2017. PubMed PMID: 28423036; PubMed Central PMCID: PMC5396926.
44. Rondinelli M, Rossi A, Gandolfi A, Saponaro F, Bucciarelli L, Adda G, Molinari C, Montefusco L, Specchia C, Chiara Rossi M, Scardapane M, Arosio M, **Genovese S**. Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function. *Clin Ther.* 2017 Jan;39(1):159-169. doi: 10.1016/j.clinthera.2016.11.001. Epub 2016 Dec 9. PubMed PMID: 27939305.
45. Rizzo M, Rizvi AA, Patti AM, Nikolic D, Giglio RV, Castellino G, Li Volti G, Caprio M, Montalto G, Provenzano V, **Genovese S**, Ceriello A. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. *Cardiovasc Diabetol.* 2016 Dec 3;15(1):162. PubMed PMID: 27912784; PubMed Central PMCID: PMC5135832.
46. Russo GT, De Cosmo S, Viazzi F, Pacilli A, Ceriello A, **Genovese S**, Guida P, Giorda C, Cucinotta D, Pontremoli R, Fioretto P; AMD-Annals Study Group.. Plasma Triglycerides and HDL-C Levels Predict the Development of Diabetic Kidney Disease in Subjects With Type 2 Diabetes: The AMD Annals Initiative. *Diabetes Care.* 2016 Dec;39(12):2278-2287. Epub 2016 Oct 4. PubMed PMID: 27703024.
47. Ceriello A, **Genovese S**, Mannucci E, Gronda E. Comment on Ferrannini et al. *Diabetes Care* 2016;39:1108-1114. Comment on Mudaliar et al. *Diabetes Care* 2016;39:1115-1122. *Diabetes Care.* 2016 Nov;39(11):e195. PubMed PMID: 27926895.
48. Pujadas G, De Nigris V, La Sala L, Testa R, **Genovese S**, Ceriello A. The pivotal role of high glucose-induced overexpression of PKC β in the appearance of glucagon-like peptide-1 resistance in endothelial cells. *Endocrine.* 2016 Nov;54(2):396-410. Epub 2015 Nov 19. PubMed PMID: 26585565.
49. Bonfigli AR, Boemi M, Festa R, Bonazzi P, Brandoni G, Spazzafumo L, Olivieri F, Ceriello A, **Genovese S**, Testa R. Randomized, double-blind, placebo-controlled trial to evaluate the effect of *Helicobacter pylori* eradication on glucose

homeostasis in type 2 diabetic patients. *Nutr Metab Cardiovasc Dis*. 2016 Oct;26(10):893-8. doi: 10.1016/j.numecd.2016.06.012. Epub 2016 Jul 1. PubMed PMID: 27480449.

50. De Cosmo S, Viazzi F, Piscitelli P, Giorda C, Ceriello A, **Genovese S**, Russo G, Guida P, Fioretto P, Pontremoli R; AMD-Annals Study Group. Blood pressure status and the incidence of diabetic kidney disease in patients with hypertension and type 2 diabetes. *J Hypertens*. 2016 Oct;34(10):2090-2098. PubMed PMID: 27457667.
51. Prattichizzo F, Giuliani A, De Nigris V, Pujadas G, Ceka A, La Sala L, **Genovese S**, Testa R, Procopio AD, Olivieri F, Ceriello A. Extracellular microRNAs and endothelial hyperglycaemic memory: a therapeutic opportunity?. *Diabetes Obes Metab*. 2016 Sep;18(9):855-67. PubMed PMID: 27161301 (Review).
52. Ceriello A, **Genovese S**, Mannucci E, Gronda E. Glucagon and heart in type 2 diabetes: new perspectives. *Cardiovasc Diabetol*. 2016 Aug 27;15(1):123. PubMed PMID: 27568179; PubMed Central PMCID: PMC5002329. (Review)
53. Ceriello A, **Genovese S**, Bosi E. The evolving frontier of diabetes therapy: The renaissance of glycemology. *Diabetes Res Clin Pract*. 2016 Aug;118:168-71. PubMed PMID: 27379449.
54. Testa R, Bonfigli AR, **Genovese S**, De Nigris V, Ceriello A. The Possible Role of Flavonoids in the Prevention of Diabetic Complications. *Nutrients*. 2016 May 20;8(5)PubMed PMID: 27213445; PubMed Central PMCID: PMC4882722. (Review)
55. La Sala L, Cattaneo M, De Nigris V, Pujadas G, Testa R, Bonfigli AR, **Genovese S**, Ceriello A. Oscillating glucose induces microRNA-185 and impairs an efficient antioxidant response in human endothelial cells. *Cardiovasc Diabetol*. 2016 Apr 30;15(1):71. doi: 10.1186/s12933-016-0390-9. PubMed PMID: 27137793; PubMed Central PMCID: PMC4852407.
56. Ceriello A, De Nigris V, Pujadas G, La Sala L, Bonfigli AR, Testa R, Uccellatore A, **Genovese S**. The simultaneous control of hyperglycemia and GLP-1 infusion normalize endothelial function in type 1 diabetes. *Diabetes Res Clin Pract*. 2016 Apr;114:64-8. doi: 10.1016/j.diabres.2016.01.019. Epub 2016 Mar 9. PubMed PMID: 27103371.
57. Ceriello A, Testa R, **Genovese S**. Clinical implications of oxidative stress and potential role of natural antioxidants in diabetic vascular complications. *Nutr Metab Cardiovasc Dis*. 2016 Apr;26(4):285-92. doi: 10.1016/j.numecd.2016.01.006. Epub 2016 Jan 19. Review. PubMed PMID: 27036849.
58. Testa R, Bonfigli AR, **Genovese S**, Ceriello A. Focus on migrants with type 2 diabetes mellitus in European Countries. *Intern Emerg Med*. 2016 Apr;11(3):319-26. doi: 10.1007/s11739-015-1350-1. Epub 2015 Dec 21. Review. PubMed PMID: 26688327.
59. Ceriello A, **Genovese S**. Atherogenicity of postprandial hyperglycemia and lipotoxicity. *Rev Endocr Metab Disord*. 2016 Mar;17(1):111-6. doi: 10.1007/s11154-016-9341-8. Review. PubMed PMID: 26880302.
60. Gentile S, Guarino G, Strollo F, Romano M, **Genovese S**, Masarone M, Ceriello A. Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus. *Diabetes Res Clin Pract*. 2016 Mar;113:179-86. doi: 10.1016/j.diabres.2015.12.006. Epub 2016 Jan 9. PubMed PMID: 26803356.
61. Schnell O, Standl E, Catrinioiu D, **Genovese S**, Lalic N, Skra J, Valensi P, Ceriello A. Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D& CVD) EASD Study Group. *Cardiovasc Diabetol*. 2016 Feb 18;15:33. doi: 10.1186/s12933-016-0357-x. PubMed PMID: 26892706; PubMed Central PMCID: PMC4758171.
62. Ceriello A, **Genovese S**. Comment on Giacco et al. GLP-1 Cleavage Product Reverses Persistent ROS Generation After Transient Hyperglycemia by Disrupting an ROS-Generating Feedback Loop. *Diabetes* 2015;64:3273-3284. *Diabetes*. 2016 Feb;65(2):e5. doi: 10.2337/db15-1344. PubMed PMID: 26798129.
63. Ceriello A, **Genovese S**, Mannucci E, Gronda E. Understanding EMPA-REG OUTCOME. *Lancet Diabetes Endocrinol*. 2015 Dec;3(12):929-30. doi: 10.1016/S2213-8587(15)00426-X. PubMed PMID: 26590680.
64. **Genovese S**, Torre E, Baccetti F. Economic Burden of Type 2 Diabetes Mellitus Treatment Strategies: A Cost Consequence Analysis of Sitagliptin vs Sulfonylureas in Lombardy Region. *Value Health*. 2015 Nov;18(7):A606. doi: 10.1016/j.jval.2015.09.2089. Epub 2015 Oct 20. PubMed PMID: 26533404.

65. Ceriello A, La Sala L, De Nigris V, Pujadas G, Testa R, Uccellatore A, **Genovese S**. GLP-1 reduces metalloproteinase-14 and soluble endoglin induced by both hyperglycemia and hypoglycemia in type 1 diabetes. *Endocrine*. 2015 Nov;50(2):508-11. doi: 10.1007/s12020-015-0565-2. Epub 2015 Mar 6. PubMed PMID: 25743265.
66. Uccellatore A, **Genovese S**, Dicembrini I, Mannucci E, Ceriello A. Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists. *Diabetes Ther*. 2015 Sep;6(3):239-56. doi: 10.1007/s13300-015-0127-x. Epub 2015 Aug 14. PubMed PMID: 26271795; PubMed Central PMCID: PMC4575308.
67. Giugliano D, Maiorino MI, Bellastella G, Petrizzo M, Ceriello A, **Genovese S**, Esposito K. Setting the hemoglobin A1c target in type 2 diabetes: a priori, a posteriori, or neither? *Endocrine*. 2015 Sep;50(1):56-60. doi: 10.1007/s12020-015-0549-2. Epub 2015 Feb 12. PubMed PMID: 25672778.
68. De Nigris V, Pujadas G, La Sala L, Testa R, **Genovese S**, Ceriello A. Short-term high glucose exposure impairs insulin signaling in endothelial cells. *Cardiovasc Diabetol*. 2015 Aug 22;14:114. doi: 10.1186/s12933-015-0278-0. PubMed PMID: 26297582; PubMed Central PMCID: PMC4546318.
69. La Sala L, Pujadas G, De Nigris V, Canivell S, Novials A, **Genovese S**, Ceriello A. Oscillating glucose and constant high glucose induce endoglin expression in endothelial cells: the role of oxidative stress. *Acta Diabetol*. 2015 Jun;52(3):505-12. doi: 10.1007/s00592-014-0670-3. Epub 2014 Nov 15. PubMed PMID: 25398480. (*Citations 1*)
70. Rondinelli M, Novara F, Calcaterra V, Zuffardi O, **Genovese S**. Wolfram syndrome 2: a novel CISD2 mutation identified in Italian siblings. *Acta Diabetol*. 2015 Feb;52(1):175-8. doi: 10.1007/s00592-014-0648-1. Epub 2014 Nov 5. PubMed PMID: 25371195.
71. Gronda E, **Genovese S**, Padeletti L, Cacciatore F, Vitale DF, Bragato R, Innocenti L, Schiano C, Sommese L, De Pascale MR, Genovese L, Abete P, Donatelli F, Napoli C. Renal function impairment predicts mortality in patients with chronic heart failure treated with resynchronization therapy. *Cardiol J*. 2015;22(4):459-66. doi: 10.5603/CJ.a2015.0019. PubMed PMID: 26325259.
72. Gallo M, Mannucci E, De Cosmo S, Gentile S, Candido R, De Micheli A, Di Benedetto A, Esposito K, **Genovese S**, Medea G, Ceriello A. Algorithms for personalized therapy of type 2 diabetes: results of a web-based international survey. *BMJ Open Diabetes Res Care*. 2015 Aug 12;3(1):e000109. doi: 10.1136/bmjdr-2015-000109. eCollection 2015. PubMed PMID: 26301097; PubMed Central PMCID: PMC4537916.
73. Ceriello A, La Sala L, De Nigris V, Pujadas G, Rondinelli M, **Genovese S**. GLP-1 reduces metalloproteinase-9 induced by both hyperglycemia and hypoglycemia in type 1 diabetes. The possible role of oxidative stress. *Ther Clin Risk Manag*. 2015 Jun 4;11:901-3. doi: 10.2147/TCRM.S83322. eCollection 2015. PubMed PMID: 26082639; PubMed Central PMCID: PMC4461018.
74. Ausili D, Bezze S, Canizzaro C, Bulgheroni M, Toolbert DJ, **Genovese S**, Di Mauro S. [Self-care assessment in type 2 diabetes patients: Italian translation and validation of the Summary of Diabetes Self-Care Activities]. *Prof Inferm*. 2015 Jan-Mar;68(1):9-18. doi: 10.7429/pi.2015.681009. Italian. PubMed PMID: 25837611.
75. Testa R, Vanhooren V, Bonfigli AR, Boemi M, Olivieri F, Ceriello A, **Genovese S**, Spazzafumo L, Borelli V, Bacalini MG, Salvioli S, Garagnani P, Dewaele S, Libert C, Franceschi C. N-glycomic changes in serum proteins in type 2 diabetes mellitus correlate with complications and with metabolic syndrome parameters. *PLoS One*. 2015 Mar 20;10(3):e0119983. doi: 10.1371/journal.pone.0119983. eCollection 2015. PubMed PMID: 25793407; PubMed Central PMCID: PMC4368037.
76. Zampetti S, Campagna G, Tiberti C, Songini M, Arpi ML, De Simone G, Cossu E, Cocco L, Osborn J, Bosi E, Giorgino F, Spoletini M, Buzzetti R; NIRAD Study Group (including **Genovese S**). High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7). *Eur J Endocrinol*. 2014 Dec;171(6):697-704. doi: 10.1530/EJE-14-0342. Epub 2014 Sep 11. PubMed PMID: 25213702.
77. Ceriello A, Esposito K, La Sala L, Pujadas G, De Nigris V, Testa R, Bucciarelli L, Rondinelli M, **Genovese S**. The protective effect of the Mediterranean diet on endothelial resistance to GLP-1 in type 2 diabetes: a preliminary report. *Cardiovasc Diabetol*. 2014 Nov 19;13(1):140. [Epub ahead of print] PubMed PMID: 25407792; PubMed Central PMCID: PMC4240857.
78. Olivieri F, Bonafè M, Spazzafumo L, Gobbi M, Prattichizzo F, Recchioni R, Marcheselli F, La Sala L, Galeazzi R, Rippo MR, Fulgenzi G, Angelini S, Lazzarini R, Bonfigli AR, Brugè F, Tiano L, **Genovese S**, Ceriello A, Boemi M, Franceschi C, Procopio AD, Testa R. Age- and glycemia-related miR-126-3p levels in plasma and endothelial cells. *Aging (Albany NY)*. 2014 Sep;6(9):771-87. PubMed PMID: 25324472; PubMed Central PMCID: PMC4221921.

79. Testa R, **Genovese S**, Ceriello A. Nutritional imbalances linking cellular senescence and type 2 diabetes mellitus. *Curr Opin Clin Nutr Metab Care*. 2014 Jul;17(4):338-42. doi: 10.1097/MCO.000000000000066. Review. PubMed PMID: 24839949.
80. Ceriello A, Novials A, Canivell S, La Sala L, Pujadas G, Esposito K, Testa R, Bucciarelli L, Rondinelli M, **Genovese S**. Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes. *Diabetes Care*. 2014 Jul;37(7):1938-43. doi: 10.2337/dc13-2618. Epub 2014 Mar 25. PubMed PMID: 24667461.
81. Esposito K, Ceriello A, **Genovese S**, Giugliano D. Cardiovascular guidelines: separate career may help attenuate controversy. *Cardiovasc Diabetol*. 2014 Mar 28;13:66. doi: 10.1186/1475-2840-13-66. PubMed PMID: 24678917; PubMed Central PMCID: PMC3973351.
82. De Cosmo S, Rossi MC, Pellegrini F, Lucisano G, Bacci S, Gentile S, Ceriello A, Russo G, Nicolucci A, Giorda C, Viazzi F, Pontremoli R; AMD-Annals Study Group (including **Genovese S**). Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes. *Nephrol Dial Transplant*. 2014 Mar;29(3):657-62. doi: 10.1093/ndt/gft506. Epub 2014 Jan 6. PMID: 24398892.
83. Ceriello A, Novials A, Ortega E, Pujadas G, La Sala L, Testa R, Bonfigli AR, **Genovese S**. Hyperglycemia following recovery from hypoglycemia worsens endothelial damage and thrombosis activation in type 1 diabetes and in healthy controls. *Nutr Metab Cardiovasc Dis*. 2014 Feb;24(2):116-23. doi: 10.1016/j.numecd.2013.05.003. Epub 2013 Oct 1. PubMed PMID: 24094827.
84. Caretto A, Primerano L, Novara F, Zuffardi O, **Genovese S**, Rondinelli M. A Therapeutic Challenge: Liddle's Syndrome Managed with Amiloride during Pregnancy. *Case Rep Obstet Gynecol*. 2014; doi: 10.1155/2014/156250. Epub 2014 Aug 25.
85. Balistreri CR, Bonfigli AR, Boemi M, Olivieri F, Ceriello A, **Genovese S**, Franceschi C, Spazzafumo L, Fabietti P, Candore G, Caruso C, Lio D, Testa R. Evidences of +896 A/G TLR4 polymorphism as an indicative of prevalence of complications in T2DM patients. *Mediators Inflamm*. 2014;2014:973139. doi: 10.1155/2014/973139. Epub 2014 Apr 2. PubMed PMID: 24803744; PubMed Central PMCID: PMC3996297.
86. Mannucci E, **Genovese S**, Monami M, Navalesi G, Dotta F, Anichini R, Romagnoli F, Gensini G. Photodynamic topical antimicrobial therapy for infected foot ulcers in patients with diabetes: a randomized, double-blind, placebo-controlled study-the DANTE (Diabetic ulcer Antimicrobial New Topical treatment Evaluation) study. *Acta Diabetol*. 2013 Dec 19;PubMed PMID: 24352342.
87. Ceriello A, Novials A, Ortega E, Canivell S, La Sala L, Pujadas G, Bucciarelli L, Rondinelli M, **Genovese S**. Vitamin C further improves the protective effect of glucagon-like peptide-1 on acute hypoglycemia-induced oxidative stress, inflammation, and endothelial dysfunction in type 1 diabetes. *Diabetes Care*. 2013 Dec;36(12):4104-8. doi: 10.2337/dc13-0750. Epub 2013 Oct 15. Erratum in: *Diabetes Care*. 2014 Jul;37(7):2063. PubMed PMID: 24130351; PubMed Central PMCID: PMC3836129.
88. Choudhary P, **Genovese S**, Reach G. Blood glucose pattern management in diabetes: creating order from disorder. *J Diabetes Sci Technol*. 2013 Nov 1;7(6):1575-84. PubMed PMID: 24351184; PubMed Central PMCID: PMC3876336.
89. Schnell O, Cappuccio F, **Genovese S**, Standl E, Valensi P, Ceriello A. Type 1 diabetes and cardiovascular disease. *Cardiovasc Diabetol*. 2013 Oct 28;12(1):156. PubMed PMID: 24165454; PubMed Central PMCID: PMC3816572.
90. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, EXAMINE Investigators (including **Genovese S**). Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *N Engl J Med*. 2013 Oct 3;369(14):1327-35. PubMed PMID: 23992602.
91. Rossi MC, Cristofaro MR, Gentile S, Lucisano G, Manicardi V, Mulas MF, Napoli A, Nicolucci A, Pellegrini F, Suraci C, Giorda C, AMD Annals Study Group (including **Genovese S**). Sex disparities in the quality of diabetes care: biological and cultural factors may play a different role for different outcomes: a cross-sectional observational study from the AMD Annals initiative. *Diabetes Care*. 2013 Oct;36(10):3162-8. PubMed PMID: 23835692; PubMed Central PMCID: PMC3781503.
92. Monami M, **Genovese S**, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. *Diabetes Obes Metab*. 2013 Oct;15(10):938-53. PubMed PMID: 23594109.
93. **Genovese S**, Passaro A, Brunetti P, Comaschi M, Cucinotta D, PRISMA study group, Egan CG, Chinea B, Bravi F, Di Pietro C. Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with

- metformin on HDL-C levels in Type 2 diabetic patients. *J Endocrinol Invest*. 2013 Sep;36(8):606-16. PubMed PMID: 23511244.
94. Ceriello A, Novials A, Ortega E, Canivell S, La Sala L, Pujadas G, Esposito K, Giugliano D, **Genovese S**. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. *Diabetes Care*. 2013 Aug;36(8):2346-50. PubMed PMID: 23564922; PubMed Central PMCID: PMC3714509.
 95. Ceriello A, Novials A, Ortega E, Canivell S, Pujadas G, La Sala L, Bucciarelli L, Rondinelli M, **Genovese S**. Vitamin C further improves the protective effect of GLP-1 on the ischemia-reperfusion-like effect induced by hyperglycemia post-hypoglycemia in type 1 diabetes. *Cardiovasc Diabetol*. 2013 Jun 27;12(1):97. PubMed PMID: 23806096; PubMed Central PMCID: PMC3699412.
 96. Garagnani P, Giuliani C, Pirazzini C, Olivieri F, Bacalini MG, Ostan R, Mari D, Passarino G, Monti D, Bonfigli AR, Boemi M, Ceriello A, **Genovese S**, Sevini F, Luiselli D, Tieri P, Capri M, Salvioli S, Vijg J, Suh Y, Delledonne M, Testa R, Franceschi C. Centenarians as super-controls to assess the biological relevance of genetic risk factors for common age-related diseases: a proof of principle on type 2 diabetes. *Aging (Albany NY)*. 2013 May;5(5):373-85. PubMed PMID: 23804578; PubMed Central PMCID: PMC3701112.
 97. **Genovese S**, Tedeschi D. Effects of vildagliptin/metformin therapy on patient-reported outcomes: work productivity, patient satisfaction, and resource utilization. *Adv Ther*. 2013 Feb;30(2):152-64. PubMed PMID: 23430354.
 98. **Genovese S**, De Berardis G, Nicolucci A, Mannucci E, Evangelista V, Totani L, Pellegrini F, Ceriello A. Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes. *Adv Ther*. 2013 Feb;30(2):190-202. PubMed PMID: 23359066.
 99. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S 3rd, Bertrand M, Fuster V, FREEDOM Trial Investigators (including **Genovese S**). Strategies for multivessel revascularization in patients with diabetes. *N Engl J Med*. 2012 Dec 20;367(25):2375-84. PubMed PMID: 23121323.
 100. Cioffi G, Giorda CB, Chinali M, Di Lenarda A, Faggiano P, Lucci D, Maggioni AP, Masson S, Mureddu GF, Tarantini L, Velussi M, Comaschi M, DYDA Investigators (including **Genovese S**). Analysis of midwall shortening reveals high prevalence of left ventricular myocardial dysfunction in patients with diabetes mellitus: the DYDA study. *Eur J Prev Cardiol*. 2012 Oct;19(5):935-43. PubMed PMID: 21798988.
 101. Salmaso S, Bersani S, Mastrotto F, Tonon G, Schrepfer R, **Genovese S**, Caliceti P. Self-assembling nanocomposites for protein delivery: supramolecular interactions between PEG-cholane and rh-G-CSF. *J Control Release*. 2012 Aug 20;162(1):176-84. PubMed PMID: 22727711.
 102. Selis F, Schrepfer R, Sanna R, Scaramuzza S, Tonon G, Dedoni S, Onali P, Orsini G, **Genovese S**. Enzymatic mono-pegylation of glucagon-like peptide 1 towards long lasting treatment of type 2 diabetes. *Results Pharma Sci*. 2012 Sep 18;2:58-65. doi: 10.1016/j.rinphs.2012.09.001. eCollection 2012. PubMed PMID: 25755995; PubMed Central PMCID: PMC4167179.
 103. Ruggerenti P, Lauria G, Iliev IP, Fassi A, Ilieva AP, Rota S, Chiurciu C, Barlovic DP, Sghirlanzoni A, Lombardi R, Penza P, Cavaletti G, Piatti ML, Frigeni B, Filipponi M, Rubis N, Noris G, Motterlini N, Ene-Iordache B, Gaspari F, Perna A, Zaletel J, Bossi A, Dodesini AR, Trevisan R, Remuzzi G, DEMAND Study Investigators (including **Genovese S**). Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. *Hypertension*. 2011 Nov;58(5):776-83. PubMed PMID: 21931073.
 104. Giorda CB, Cioffi G, de Simone G, Di Lenarda A, Faggiano P, Latini R, Lucci D, Maggioni AP, Tarantini L, Velussi M, Verdecchia P, Comaschi M, DYDA Investigators (including **Genovese S**). Predictors of early-stage left ventricular dysfunction in type 2 diabetes: results of DYDA study. *Eur J Cardiovasc Prev Rehabil*. 2011 Jun;18(3):415-23. PubMed PMID: 21450640.
 105. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G, ROADMAP Trial Investigators (including **Genovese S**). Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. *N Engl J Med*. 2011 Mar 10;364(10):907-17. PubMed PMID: 21388309.
 106. Gruppo di studio ANNALI AMD (including **Genovese S**). [AMD Annals: a model of continuous monitoring and improvement of the quality of diabetes care]. *Epidemiol Prev*. 2011 Jan-Feb;35(1):18-26. PubMed PMID: 21436491.

107. Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM, van Es GA, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Fitzgerald PJ, Nesto RW, APPROACH Study Group (including **Genovese S**). Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. *Circulation*. 2010 Mar 16;121(10):1176-87. PubMed PMID: 20194881.
108. Gronda E, Aronica A, Visconti M, Di Malta A, Pini D, Mangiavacchi M, Andreuzzi B, Municinò A, **Genovese S**, Morengi E. [Gender differences of at risk patients with overt heart failure in the real world of general practice Data from the GIPSI (Gestione Integrata Progetto Scopenso in Italia) registry]. *G Ital Cardiol (Rome)*. 2010 Mar;11(3):233-8. PubMed PMID: 20550064.
109. Lodigiani C, Ferrazzi P, Di Micco P, Librè L, **Genovese S**, Quaglia I, Rota LL. Is there a relationship between factor V Leiden and type 2 diabetes?. *J Transl Med*. 2009 Jun 26;7:52. PubMed PMID: 19558686; PubMed Central PMCID: PMC2708136.
110. Mangiavacchi M, Gasparini M, **Genovese S**, Pini D, Klersy C, Bragato R, Andreuzzi B, Municinò A, Regoli F, Galimberti P, Ceriotti C, Gronda E. Insulin-treated type 2 diabetes is associated with a decreased survival in heart failure patients after cardiac resynchronization therapy. *Pacing Clin Electrophysiol*. 2008 Nov;31(11):1425-32. PubMed PMID: 18950300.
111. Corrada E, Cappelleri A, Belli G, **Genovese S**, Barbaro C, Gasparini G, Pagnotta P, Rossi M, Zavalloni D, Presbitero P. Admission glycemia and markers of inflammation are independent outcome predictors in primary PCI in non-diabetic patients. *Minerva Cardioangiol*. 2008 Oct;56(5):445-52. PubMed PMID: 18813179.
112. **Genovese S**, Bazzigaluppi E, Gonçalves D, Ciucci A, Cavallo MG, Purrello F, Anello M, Rotella CM, Bardini G, Vaccaro O, Riccardi G, Travaglini P, Morengi E, Bosi E, Pozzilli P. Clinical phenotype and beta-cell autoimmunity in Italian patients with adult-onset diabetes. *Eur J Endocrinol*. 2006 Mar;154(3):441-7. PubMed PMID: 16498058.
113. Paroni R, Comuzzi B, Arcelloni C, Brocco S, de Kreutzenberg S, Tiengo A, Ciucci A, Beck-Peccoz P, **Genovese S**. Comparison of capillary electrophoresis with HPLC for diagnosis of factitious hypoglycemia. *Clin Chem*. 2000 Nov;46(11):1773-80. PubMed PMID: 11067812.
114. Bingley PJ, Bonifacio E, Williams AJ, **Genovese S**, Bottazzo GF, Gale EA. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. *Diabetes*. 1997 Nov;46(11):1701-10. PubMed PMID: 9356015.
115. **Genovese S**, Bonfanti R, Bazzigaluppi E, Lampasona V, Benazzi E, Bosi E, Chiumello G, Bonifacio E. Association of IA-2 autoantibodies with HLA DR4 phenotypes in IDDM. *Diabetologia*. 1996 Oct;39(10):1223-6. PubMed PMID: 8897011.
116. Lampasona V, Bearzatto M, **Genovese S**, Bosi E, Ferrari M, Bonifacio E. Autoantibodies in insulin-dependent diabetes recognize distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen. *J Immunol*. 1996 Sep 15;157(6):2707-11. PubMed PMID: 8805677.
117. Bonifacio E, Lampasona V, **Genovese S**, Ferrari M, Bosi E. Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. *J Immunol*. 1995 Dec 1;155(11):5419-26. PubMed PMID: 7594559.
118. Lampasona V, Ferrari M, Bonifacio E, Pastore MR, Carrera P, Sergi A, **Genovese S**, Trucco M, Dorman J, Bosi E. HLA-DQ screening for risk assessment of insulin dependent diabetes in northern Italy. *Acta Diabetol*. 1995 Oct;32(3):137-42. PubMed PMID: 8590780.
119. Passini N, Larigan JD, **Genovese S**, Appella E, Sinigaglia F, Rogge L. The 37/40-kilodalton autoantigen in insulin-dependent diabetes mellitus is the putative tyrosine phosphatase IA-2. *Proc Natl Acad Sci U S A*. 1995 Sep 26;92(20):9412-6. PubMed PMID: 7568143; PubMed Central PMCID: PMC40995.
120. Bonifacio E, **Genovese S**, Braghi S, Bazzigaluppi E, Lampasona V, Bingley PJ, Rogge L, Pastore MR, Boggetti E, Bottazzo GF. Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. *Diabetologia*. 1995 Jul;38(7):816-22. PubMed PMID: 7556984.
121. Christie MR, **Genovese S**, Cassidy D, Bosi E, Brown TJ, Lai M, Bonifacio E, Bottazzo GF. Antibodies to islet 37k antigen, but not to glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity. *Diabetes*. 1994 Oct;43(10):1254-9. PubMed PMID: 7926297.

122. **Genovese S**, Bingley PJ, Bonifacio E, Christie MR, Shattock M, Bonfanti R, Foxon R, Gale EA, Bottazzo GF. Combined analysis of IDDM-related autoantibodies in healthy schoolchildren. *Lancet*. 1994 Sep 10;344(8924):756. PubMed PMID: 7915802.
123. Marshall MO, Høyer PE, Petersen JS, Hejnaes KR, **Genovese S**, Dyrberg T, Bottazzo GF. Contribution of glutamate decarboxylase antibodies to the reactivity of islet cell cytoplasmic antibodies. *J Autoimmun*. 1994 Aug;7(4):497-508. PubMed PMID: 7980851.
124. Wagner R, Bonifacio E, Bingley PJ, **Genovese S**, Reinwein D, Bottazzo GF. Low interleukin-2 receptor levels in serum of patients with insulin-dependent diabetes. *Clin Investig*. 1994 Jul;72(7):494-8. PubMed PMID: 7981575.
125. Wagner R, McNally JM, Bonifacio E, **Genovese S**, Foulis A, McGill M, Christie MR, Betterle C, Bosi E, Bottazzo GF. Lack of immunohistological changes in the islets of nondiabetic, autoimmune, polyendocrine patients with beta-selective GAD-specific islet cell antibodies. *Diabetes*. 1994 Jul;43(7):851-6. PubMed PMID: 7912208.
126. Wagner R, **Genovese S**, Bosi E, Becker F, Bingley PJ, Bonifacio E, Miles KA, Christie MR, Bottazzo GF, Gale EA. Slow metabolic deterioration towards diabetes in islet cell antibody positive patients with autoimmune polyendocrine disease. *Diabetologia*. 1994 Apr;37(4):365-71. PubMed PMID: 8063036.
127. Wagner R, **Genovese S**, Bonifacio E, Bosi E, Bingley PJ, Bottazzo GF. Abnormal serum neopterin levels in patients with polyendocrine autoimmunity and islet cell antibodies. *Diabetes, Nutrition and Metabolism - Clinical and Experimental*. 1994;7(1):11-16.
128. Dozio N, Belloni C, Girardi AM, **Genovese S**, Sodoyez JC, Bottazzo GF, Pozza G, Bosi E. Heterogeneous IgG subclass distribution of islet cell antibodies. *J Autoimmun*. 1994 Feb;7(1):45-53. PubMed PMID: 8198701.
129. **Genovese S**, Bonifacio E, McNally JM, Dean BM, Wagner R, Bosi E, Gale EA, Bottazzo GF. Distinct cytoplasmic islet cell antibodies with different risks for type 1 (insulin-dependent) diabetes mellitus. *Diabetologia*. 1992 Apr;35(4):385-8. PubMed PMID: 1516768.
130. Bottazzo GF, **Genovese S**, Bosi E, Dean BM, Christie MR, Bonifacio E. Novel considerations on the antibody/autoantigen system in type I (insulin-dependent) diabetes mellitus. *Ann Med*. 1991 Oct;23(4):453-61. Review. PubMed PMID: 1930942.